🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.

Recruitingn/aAges any - 18 YearsAllUniversity Hospital, Limoges
NCT04207580 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Pediatric idiopathic nephrotic syndrome (INS) is a rare disease for which the optimal therapeutic strategy has not yet been defined. A network of clinicians treating complicated forms of this disease (grouped within the Société de Néphrologie Pédiatrique, SNP) exists, but to date there is no prospective cohort following up these patients that would facilitate the development of cohort-nested trials. This absence of structured follow up makes it difficult to set up prospective studies. The main objective is to create a prospective cohort of pediatric INS patients to collect cases treated in SNP centers, to study their epidemiological characteristics, and to provide a basis for comparison for future cohort-nested trials.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient under 18 years of age * With idiopathic nephrotic syndrome (according to SPN criteria) beginning after January 1, 2018 * Child seen at least once in consultation or hospitalization by a pediatrician member of the Society of Pediatric Nephrology * Residing in France * Consent signed by parents and patient's agreement to participate (if of age) * Affiliated to a social security system. Exclusion Criteria: * Refusal of the patient or legal representatives to participate in the cohort
💊

What it tests

  • Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome,
📍

Where

48 sites
CH d'Agen
Agen, France
CHU d'Amiens
Amiens, France
CHU d'Auxerre
Auxerre, France
CH de la côte basque
Bayonne, France
CHU de Besançon
Besançon, France
CHU de Boredeaux
Bordeaux, France
CHU de Brest
Brest, France
HCL Lyon
Bron, France

…and 40 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy